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sympathetic denervation in resistant
hypertensive patients failure: What to do?As reported in the SYMPLICITY HTN-3 trial [1], no signiﬁcant differ-
ences in the 24-h ABPM were observed between 6 and 12 months in
the denervation and crossover subjects. Ambulatory datawere available
for only 20 of 70 (29%) non-crossover subjects at 12 months, given that
ABPM was not protocol-mandated for these subjects at this time point.
However, in these 20 subjects, a pattern similar to that of ofﬁce readings
was observed, showing a larger 24-h ABPM reduction at 6 than 12
months (−11.0 ± 19.5 vs.−6.1 ± 14.4 mmHg at 6 and 12months, re-
spectively; P = 0.272) [1]. Moreover, we did not observe the change in
24-h ABPM as expected in our study even patients presenting resistant
hypertension after antihypertensive staggered scheme andRSD and one
predictor of success that is the baseline ofﬁce systolic blood pressure of
≥180 mmHg [2]. Based on these results we performed a second RSD
procedure, aiming to low the blood pressure in these resistant hyper-
tensive patients.
This prospective, longitudinal study was conducted in 27 patients
with resistant hypertension who underwent percutaneous RSD. The
study was approved by the Hospital e Clínica São Gonçalo Ethics Com-
mittee andwas conducted in accordancewith the principles of the Dec-
laration of Helsinki. All patients signed written informed consent prior
to study inclusion. We evaluated the safety and effectiveness of RSD
for improvement of clinical parameters and in reducing damage to the
heart, through echocardiographic parameters, and kidneys, by assessing
estimated glomerular ﬁltration rate (eGFR) and albumin:creatinine
ratio (ACR), in patients with resistant hypertension. This studywas con-
ducted at the Hospital e Clínica São Gonçalo, Rio de Janeiro, Brazil,
where patients were recruited from January 2014 through to July
2015 from the Artiﬁcial Cardiac Pacing Department. Patients meeting
all the following criteria were consecutively enrolled: (i) ofﬁce systolic
BP ≥140 mmHg despite using 3 antihypertensive drugs, being one of
them a diuretic; (ii) aged between 18 and 80 years; (iii) undergoing an-
tihypertensive staggered schemewith the following drugs for at least 6
months before being subjected to the ﬁrst RSD procedure: β blocker
followed by spironolactone, followed by α-1 adrenergic receptor
blocker and after by α-2 adrenergic receptor blocker, in case of no re-
duction of blood pressure; (iv) left ventricular ejection fraction N50%
measured by Simpson's method in the echocardiogram; (v) sinus
rhythm; (vi) eGFR determined using the Chronic Kidney Disease Epide-
miology Collaboration (CKD-EPI) equation, eGFR [3] N60 mL/min/1.73
m2 these patients without microalbuminuria); and (vii) able to read,
understand and sign the informed consent form. Patients with any of
the following criteria were excluded: (i) pregnancy; (ii) acute HF; (iii)
acute coronary syndrome; (iv) valvular disease with signiﬁcant hemo-
dynamic repercussions; (v) myocardial infarction, unstable angina,
stroke or transient ischemic attack within the previous 6 months; (vi)
renovascular abnormalities (including severe renal artery stenosis,http://dx.doi.org/10.1016/j.ijcme.2016.09.006
2214-7624/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access articland renal angioplasty with or without stenting); (vii) psychiatric dis-
ease; (viii) allergy to ionic contrast; (ix) unable to be followed clinically
after the procedure; (x) known to have drug or alcohol addiction,which
can affect the ability to understand or followmedical instructions; (xi) a
serious disease, which in the opinion of the investigator, may adversely
affect the safety and/or efﬁcacy of the participant or the study.
Transthoracic echocardiography was performed at baseline and at 6
months after RSD using a GE ultrasound system (Vivid I, General Elec-
tric, Frankfurt, Germany) equipped with a multi-frequency transducer
and tissue Doppler imaging software according to the Guidelines of
the American Society of Echocardiography [4]. Data were analyzed
and interpreted by one experienced echocardiographer blinded to treat-
ment status, HF stage, and the sequence of the images. Left ventricular
(LV)masswas calculated from LV linear dimensions using theDevereux
formula [4,5]. LVmasswas indexed to body surface area [4,6], as indicat-
ed. The ABPMwas performed for 24 h with a clinically validated device
(CardioMapa; Cardios, São Paulo, Brazil) at baseline. The devicewas de-
signed to measure every 15 min during daytime (from 6 to 22 h) and
every 30 min during the night (from 22 to 6 h). The patients were
instructed to continue their regular activities during recording and go
to the bed not later than 23:00 h. The wakefulness ranged from 8 to
22 h and the sleep period from midnight till 6:00 am [7]. All subjects
were trained to record in a diary the hours during which they took
their meals, as well as periods of sleep and wakefulness, ingestion of
drugs, in addition to symptoms and events that could inﬂuence blood
pressure during this period. The measurements were transferred to a
computer for analysis. The monitoring was repeated as necessary until
≥70% of day and night values measured were satisfactory [8].
In total, 27 hypertensive resistant patientswere treated in this study.
All patients underwent a complete medical history and physical exam-
ination, and their HF medication was reviewed. Blood pressure was
measured in the standing, sitting, and supine positions on at least two
subsequent visits in both arms. Blood samples were collected to deter-
mine a complete blood count, and biochemistry (including serum creat-
inine to estimate GFR). Urine samples were obtained to determine
albuminuria, protein, and creatinine levels. Twenty-four hour ambula-
tory BPmonitoring (ABPM), echocardiogram, and Echo Doppler evalua-
tion of the anatomy of the renal arteries of patients were also assessed.
To evaluate the true effects of RSD on resistant hypertension, baseline
antihypertensive staggered scheme was unchanged for at least 6
months before 1st RSD procedure and treatment were maintained at
follow-up. Patients were instructed not to change their medication
and dosages after the procedure unless clinically indicated. For all pa-
tients, drug records and adherence were comprehensively reviewed
and documented at each visit. The RSD procedure has been described
in detail previously [9]. Samples were collected for blood and urine
tests to monitor variables. In addition, 24-hour ABPM, and echocardio-
gram were performed at 6 (2nd RSD procedure) and 12 months after
the 1st RSD. Echo Doppler was also performed to evaluate the anatomy
of the renal arteries of patients at 6months after RSD. The following var-
iables were monitored during the follow-up period: echocardiographice under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
General features of patients at baseline.
N 27
Age, years 58 ± 9
Body mass index, kg/m2 29.5 ± 4.0
Male sex, % 20 (74%)
White ethnicity, % 16 (59%)
Hypertension, % 27 (100%)
Type 2 Diabetes Mellitus, % 13 (48%)
Coronary artery disease, % 8 (30%)
eGFR, mL/min/1.73 m2 (CKD-EPI) 83.0 ± 26.5
LVEF (Simpson),% 57.8 ± 6.4
Ofﬁce blood pressure, mmHg 187 ± 18/133 ± 10
24-hour ABPM, mmHg 156 ± 13/123 ± 15
Antihypertensive agents
ACE-inhibitor/ARB 27 (100%)
Diuretic 27 (100%)
DHP Ca++ channel blocker 27 (100%)
β blocker 27 (100%)
Spironolactone 27 (100%)
α-1 Adrenergic receptor blocker 27 (100%)
α-2 Adrenergic agonist 27 (100%)
Values are presented as mean ± SD or %; ABPM, ambulatory blood pressure measure-
ments; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CKD-
EPI, Chronic Kidney Disease Epidemiology Collaboration; DHP, dihydropyridine; eGFR, es-
timated glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; N, number of
patients.
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albuminuria.
Results are expressed as the mean and standard deviation (mean±
SD), in the case of normal distribution, or as the median with inter-
quartile range. Statistical testswere all two sided. Comparisons between
two-paired values were performed by the paired t-test in the case of
Gaussian distribution or, alternatively, by the Wilcoxon test. Compari-
sons between more than two-paired values were performed by
ANOVA for repeatedmeasures orwith Kruskal–Wallis ANOVAas appro-
priate, complemented by a post hoc test. Frequencies were compared
with Fisher's exact test. P-values b0.05 were considered statisticallyTable 2
Renal function at baseline vs. 6th and 12th month of follow-up.
Variable Baseline (n = 27)
1st RSD
6th month (n = 27)
2nd RSD
P value
6th month vs. b
Creatinine, mg/dL 1.00 ± 0.65 1.10 ± 0.36 0.6875
eGFR, mL/min/1.73m2 83.0 ± 26.5 73.7 ± 21.4 0.2772
ACR, mg/g 13.4 ± 8.0 16.9 ± 6.5 0.2337
Values are presented as mean ± SD; ACR, albumin:creatinine ratio; eGFR, estimated glomerula
Fig. 1.No changes happened in ofﬁce (A) and 24-h ABPM (B) systolic (red bars)/diastolic (gray
SD; ABPM, ambulatory blood pressure measurements.signiﬁcant. Correlations between two variables were performed by the
Pearson method in the case of Gaussian distribution or, alternatively,
with the Spearman correlation test. All statistical analyses were per-
formed using Graphpad Prism version 7.0 (Graphpad software, La
Jolla, CA, USA).
General baseline characteristics of the 27 resistant hypertensive pa-
tients are listed in Table 1. Mean ofﬁce systolic/diastolic BP was 187 ±
18/133 ± 10 mmHg. Mean Left ventricular ejection fraction (LVEF)
was 57.8 ± 6.4%. No patient was re-admitted for procedural complica-
tions during follow-up. No hypotensive (systolic BP b90 mmHg) [10]
or syncopal episodes were reported. Real-time renal artery imaging
was performed to assess potential structural changes related to the pro-
cedure. Some small focal irregularities of the renal arteries that were
present during the procedure (possibly due to minor spasm or
edema) were no longer seen postoperatively. At 6 months post-
procedure, all patients underwent a Doppler scan of renal arteries, and
there was no evidence of stenosis or ﬂow limitation. Effects of RSD on
creatinine values, eGFR, and albumin:creatinine ratio is also shown in
Table 2. At baseline after the 1st RSD procedure the systolic/diastolic of-
ﬁce blood pressure were 187 ± 18/133 ± 10 mmHg, at 6 months of
follow-up the ofﬁce blood pressure was 185 ± 13/129 ± 16 mmHg
and the 2nd RSD was performed, and at 12 months of follow-up the of-
ﬁce blood pressurewas 188± 16/132± 13mmHg (P= 0.8878/0.3169
for baseline vs. 6th month, P = 0.9706/0.9295for baseline vs. 12th
month, and P = 0.7656/0.5211 for 6th vs. 12th month), as shown in
Fig. 1A. The same occurred with the 24-hour ABPM, at baseline after
the 1st RSD procedure the systolic/diastolic 24-hour ABPM were
156 ± 13/123 ± 15 mmHg, at 6 months of follow-up the 24-hour
ABPMwas 158± 20/128± 12mmHg and the 2nd RSDwas performed,
and at 12 months of follow-up the 24-hour ABPMwas 155 ± 17/124 ±
16 mmHg (P = 0.9013/0.4147 for baseline vs. 6th month, P = 0.9743/
0.9649 for baseline vs. 12th month, and P = 0.7919/0.5677 for 6th vs.
12th month), as shown in Fig. 1B. Table 3 shows the effects of RSD at
baseline, 6, and 12 months of follow-up on echocardiographic parame-
ters: LVEF, end diastolic left ventricular diameter (EDLVD), end diastolic
left ventricular volume (EDLVV), end systolic left ventricular diameter
(ESLVD), end systolic left ventricular volume (ESLVV), left ventricularaseline
12th month (n = 27)
End of follow-up
P value
12th month vs. baseline
P value
6th vs. 12th month
1.12 ± 0.20 0.5838 0.9850
72.3 ± 17.7 0.1851 0.9708
14.6 ± 8.8 0.8399 0.5293
r ﬁltration rate; RSD, renal sympathetic denervation.
bars) blood pressure during the 12months of follow-up. Values are presented asmean ±
Table 3
Echocardiographic parameters at baseline vs. 6th and 12th month of follow-up.
Variable Baseline (n = 27)
1st RSD
6th month (n = 27)
2nd RSD
P value
6th month vs. baseline
12th month (n = 27)
End of follow-up
P value
12th month vs. baseline
P value
6th vs. 12th month
LVEF (Simpson), % 57.8 ± 6.4 60.0 ± 8.8 0.5364 59.3 ± 7.3 0.7474 0.9383
EDLVD, mm 54.4 ± 4.0 51.4 ± 2.9 0.0020 50.0 ± 2.2 b0.0001 0.2322
EDLVV, mL 190.2 ± 11.3 177.8 ± 8.4 b0.0001 173.6 ± 9.0 b0.0001 0.2519
ESLVD, mm 45.8 ± 3.3 42.6 ± 2.0 b0.0001 41.4 ± 2.1 b0.0001 0.1976
ESLVV, mL 76.5 ± 8.8 71.2 ± 7.3 0.0295 69.6 ± 6.1 0.0031 0.7129
LV mass, g/m2 135.8 ± 14.2 116.8 ± 13.7 b0.0001 110.4 ± 15.1 b0.0001 0.2354
EDPWT, mm 12.3 ± 1.0 11.0 ± 0.8 b0.0001 10.6 ± 0.6 b0.0001 0.1763
EDIVST, mm 10.8 ± 0.8 10.1 ± 0.7 0.0012 10.0 ± 0.7 0.0002 0.8587
Values are presented asmean±SD. LVEF, left ventricular ejection fraction; EDLVD, end diastolic left ventricular diameter; EDLVV, end diastolic left ventricular volume; ESLVD, end systolic
left ventricular diameter; ESLVV, end systolic left ventricular volume; LV, left ventricular; EDPWT, end diastolic posterior wall thickness; EDIVST, end diastolic inter ventricular septum
thickness; RSD, renal sympathetic denervation.
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inter ventricular septum thickness (EDIVST). Compared with baseline,
some parameters were statistically signiﬁcantly changed at both 6 and
12 months of follow-up.
This studywas a safety evaluation andwas therefore neither blinded
nor powered to assess clinical efﬁcacy. The use of echo Doppler to assess
damage in the renal arteries is in someway a limitation. However, early
complications caused by the RF applications were excluded by angiog-
raphy performed at the end of the procedure. Any other method, such
as computed tomography angiography or a new angiography of the
renal arteries, could expose patients to additional undesirable toxic in-
sults. Angiography using CO2 is not available at our center. In addition,
more precise methods for the assessment of GFR, such as cystatin C or
iothalamate, should be used in future studies to conﬁrm our ﬁndings re-
garding the effects of RSD upon eGFR, especially considering that only
one measurement of serum creatinine was performed at each time
point in our study.
Many of the echocardiographic parameters reported above im-
proved evenwithout a reduction in blood pressure after two RSD proce-
dures. However, we did not have successful in renal function
improvement or in decrease blood pressure, even after patients under-
going antihypertensive staggered scheme at least 6 months and two
RSD procedures. What to do in these cases?
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